179 related articles for article (PubMed ID: 9541944)
1. [Cytogenetic changes in prostatic carcinoma].
Sauter G; Bubendorf L; Moch H; Gasser TC; Mihatsch MJ
Pathologe; 1998 Jan; 19(1):63-8. PubMed ID: 9541944
[TBL] [Abstract][Full Text] [Related]
2. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping.
Cher ML; Bova GS; Moore DH; Small EJ; Carroll PR; Pin SS; Epstein JI; Isaacs WB; Jensen RH
Cancer Res; 1996 Jul; 56(13):3091-102. PubMed ID: 8674067
[TBL] [Abstract][Full Text] [Related]
3. Genetic alterations in hormone-refractory recurrent prostate carcinomas.
Nupponen NN; Kakkola L; Koivisto P; Visakorpi T
Am J Pathol; 1998 Jul; 153(1):141-8. PubMed ID: 9665474
[TBL] [Abstract][Full Text] [Related]
4. Chromosomal aberrations in prostate cancer.
Saramaki O; Visakorpi T
Front Biosci; 2007 May; 12():3287-301. PubMed ID: 17485299
[TBL] [Abstract][Full Text] [Related]
5. Chromosomal basis of adenocarcinoma of the prostate.
Verma RS; Manikal M; Conte RA; Godec CJ
Cancer Invest; 1999; 17(6):441-7. PubMed ID: 10434955
[TBL] [Abstract][Full Text] [Related]
6. Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer.
El Gammal AT; Brüchmann M; Zustin J; Isbarn H; Hellwinkel OJ; Köllermann J; Sauter G; Simon R; Wilczak W; Schwarz J; Bokemeyer C; Brümmendorf TH; Izbicki JR; Yekebas E; Fisch M; Huland H; Graefen M; Schlomm T
Clin Cancer Res; 2010 Jan; 16(1):56-64. PubMed ID: 20028754
[TBL] [Abstract][Full Text] [Related]
7. Chromosome 16 in primary prostate cancer: a microsatellite analysis.
Osman I; Scher H; Dalbagni G; Reuter V; Zhang ZF; Cordon-Cardo C
Int J Cancer; 1997 May; 71(4):580-4. PubMed ID: 9178811
[TBL] [Abstract][Full Text] [Related]
8. Chromosomal clues to the development of prostate tumors.
Brothman AR; Maxwell TM; Cui J; Deubler DA; Zhu XL
Prostate; 1999 Mar; 38(4):303-12. PubMed ID: 10075010
[TBL] [Abstract][Full Text] [Related]
9. Molecular biology of progression of prostate cancer.
Nupponen N; Visakorpi T
Eur Urol; 1999; 35(5-6):351-4. PubMed ID: 10325488
[TBL] [Abstract][Full Text] [Related]
10. Molecular genetics of prostate cancer.
Visakorpi T
Ann Chir Gynaecol; 1999; 88(1):11-6. PubMed ID: 10230676
[TBL] [Abstract][Full Text] [Related]
11. Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer.
Cher ML; MacGrogan D; Bookstein R; Brown JA; Jenkins RB; Jensen RH
Genes Chromosomes Cancer; 1994 Nov; 11(3):153-62. PubMed ID: 7530484
[TBL] [Abstract][Full Text] [Related]
12. Identification of genetic markers for prostatic cancer progression.
Alers JC; Rochat J; Krijtenburg PJ; Hop WC; Kranse R; Rosenberg C; Tanke HJ; Schröder FH; van Dekken H
Lab Invest; 2000 Jun; 80(6):931-42. PubMed ID: 10879743
[TBL] [Abstract][Full Text] [Related]
13. Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features.
Alers JC; Krijtenburg PJ; Vis AN; Hoedemaeker RF; Wildhagen MF; Hop WC; van Der Kwast TT; Schröder FH; Tanke HJ; van Dekken H
Am J Pathol; 2001 Feb; 158(2):399-406. PubMed ID: 11159178
[TBL] [Abstract][Full Text] [Related]
14. Genetic aberrations in prostate carcinoma detected by comparative genomic hybridization and microsatellite analysis: association with progression and angiogenesis.
Strohmeyer DM; Berger AP; Moore DH; Bartsch G; Klocker H; Carroll PR; Loening SA; Jensen RH
Prostate; 2004 Apr; 59(1):43-58. PubMed ID: 14991865
[TBL] [Abstract][Full Text] [Related]
15. DNA sequence copy number aberrations in prostate cancers: a comparison of comparative genomic hybridization data between Japan and European countries.
Matsuda K; Matsuyama H; Hara T; Yoshihiro S; Oga A; Kawauchi S; Furuya T; Izumi H; Naito K; Sasaki K
Cancer Genet Cytogenet; 2004 Jul; 152(2):119-23. PubMed ID: 15262429
[TBL] [Abstract][Full Text] [Related]
16. P53 mutations and loss of heterozygosity on chromosomes 8p, 16q, 17p, and 18q are confined to advanced prostate cancer.
Massenkeil G; Oberhuber H; Hailemariam S; Sulser T; Diener PA; Bannwart F; Schäfer R; Schwarte-Waldhoff I
Anticancer Res; 1994; 14(6B):2785-90. PubMed ID: 7872719
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor gene amplification and protein expression in recurrent prostate cancer.
Ford OH; Gregory CW; Kim D; Smitherman AB; Mohler JL
J Urol; 2003 Nov; 170(5):1817-21. PubMed ID: 14532783
[TBL] [Abstract][Full Text] [Related]
18. Discovery of new DNA amplification loci in prostate cancer by comparative genomic hybridization.
El Gedaily A; Bubendorf L; Willi N; Fu W; Richter J; Moch H; Mihatsch MJ; Sauter G; Gasser TC
Prostate; 2001 Feb; 46(3):184-90. PubMed ID: 11170146
[TBL] [Abstract][Full Text] [Related]
19. Loss of the 17p chromosomal region in a metastatic carcinoma of the prostate.
Macoska JA; Powell IJ; Sakr W; Lane MA
J Urol; 1992 Apr; 147(4):1142-6. PubMed ID: 1552612
[TBL] [Abstract][Full Text] [Related]
20. Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone.
Alers JC; Krijtenburg PJ; Rosenberg C; Hop WC; Verkerk AM; Schröder FH; van der Kwast TH; Bosman FT; van Dekken H
Lab Invest; 1997 Nov; 77(5):437-48. PubMed ID: 9389787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
